$5.06
-0.27 (-4.98%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PAVM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion SystemNCT06037265Primary PerformanceOpen-label · Treatment | Not applicable | Completed | Device: PAVmed PortIO™ Intraosseous Infusion System | Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Poor Vascular Access | 15 | 2024-07-29actual | 2025-06-27 |
| PAVmed CarpX Device Clinical StudyNCT03747510Device Safety defined as freedom from Serious Adverse Events probably or definitely related to the CarpX device resulting in significant morbidity.Open-label · Treatment | Not applicable | Completed | Device: CarpX Device | Carpal Tunnel Syndrome | 20 | 2019-12-30actual | 2020-05-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19